Pancreatitis pain quality changes at year 1 follow-up, but GP130 remains a biomarker for pain

doi:10.1016/j.pan.2024.09.016

Pancreatitis pain quality changes at year 1 follow-up, but GP130 remains a biomarker for pain

Producción científica: Article › revisión exhaustiva

Resumen

Background/objectives: Debilitating abdominal pain is a common symptom affecting patients with chronic pancreatitis (CP). CP pain is dynamic due to multiple underlying mechanisms. The objective of this study was to 1) evaluate changes in pain phenotype at one year follow-up and 2) validate putative pain biomarkers in a prospective cohort study. Methods: The Neuropathic and Nociceptive PROMIS-PQ questionnaires were used to classify pain for participants with in the PROCEED study. Putative serum biomarkers were measured via immunoassay. Results: At enrollment, 17.6 % (120/681) subjects with CP reported no pain in the previous year. Of those, 29 % experienced pain during the 1 yr follow-up whereas 18 % of those with pain prior to enrollment reported no pain during the 1 yr follow-up period. Of the 393 subjects with PROMIS-PQ data at enrollment, 212 also had follow-up data at 1 yr. Approximately half (53.3 %) of those individuals changed pain phenotype between baseline and follow-up. At 1 yr, serum TGFβ1 level was negatively correlated with nociceptive T-scores (p = 0.006). GP130 was significantly correlated with both nociceptive (p = 0.012) and neuropathic T-scores (p = 0.043) at 1 yr, which is consistent with the previously published findings. Conclusions: The positive association between TGFβ1 and pain is not maintained over time, suggesting it is a poor pain biomarker. However, serum GP130 is a consistent biomarker for mixed-type pain in CP. Preclinical studies show that targeting TGFβ1 or IL-6 (ligand for GP130) is sufficient to inhibit CP pain supporting further investigation of this as a potential therapeutic target.

Idioma original	English
Páginas (desde-hasta)	993-1002
Número de páginas	10
Publicación	Pancreatology
Volumen	24
N.º	7
DOI	https://doi.org/10.1016/j.pan.2024.09.016
Estado	Published - nov 2024

Nota bibliográfica

Publisher Copyright:
© 2024 IAP and EPC

Financiación

PROspective Evaluation of Chronic Pancreatitis for EpidEmiologic and Translational StuDies (PROCEED) is funded through the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC) which is sponsored by the National Cancer Institute and National Institute of Diabetes and Digestive and Kidney Diseases. PROCEED is a prospective observational study of US adult subjects across the pancreatitis spectrum (ranging from no pancreas disease to acute to CP) [24]. Subjects were enrolled at 9 participating clinical centers: University of Pittsburgh Medical Center, Indiana University School of Medicine, Mayo Clinic, Baylor College of Medicine, University of Florida, The Ohio State University Wexner Medical Center, Cedars-Sinai Medical Center, Stanford University School of Medicine, and Kaiser Permanente.This work was supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): R21DK122293 and K01DK120737 (JLS). The National Cancer Institute (NCI) and NIDDK for the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC) under award numbers: U01DK108288(Mayo Clinic), U01DK108300 (Stanford), U01DK108306(University of Pittsburgh Medical Center), U01DK108314(Cedars-Sinai Medical Center), U01DK108323(Indiana University), U01DK108326(Baylor College of Medicine), U01DK108327(The Ohio State University), U01DK108332(Kaiser Permanente), U01DK108320(University of Florida) and U01DK108328(MD Anderson). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. PROspective Evaluation of Chronic Pancreatitis for EpidEmiologic and Translational StuDies (PROCEED) is funded through the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC) which is sponsored by the National Cancer Institute and National Institute of Diabetes and Digestive and Kidney Diseases . PROCEED is a prospective observational study of US adult subjects across the pancreatitis spectrum (ranging from no pancreas disease to acute to CP) [ 24 ]. Subjects were enrolled at 9 participating clinical centers: University of Pittsburgh Medical Center, Indiana University School of Medicine, Mayo Clinic, Baylor College of Medicine, University of Florida, The Ohio State University Wexner Medical Center, Cedars-Sinai Medical Center, Stanford University School of Medicine, and Kaiser Permanente. This work was supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): R21DK122293 and K01DK120737 (JLS). The National Cancer Institute (NCI) and NIDDK for the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC) under award numbers: U01DK108288(Mayo Clinic), U01DK108300 (Stanford), U01DK108306(University of Pittsburgh Medical Center), U01DK108314( Cedars-Sinai Medical Center ), U01DK108323 ( Indiana University ), U01DK108326 ( Baylor College of Medicine ), U01DK108327 ( The Ohio State University ), U01DK108332 ( Kaiser Permanente ), U01DK108320 ( University of Florida ) and U01DK108328 (MD Anderson). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Financiadores	Número del financiador
Mayo Clinic Rochester
Pancreatic Cancer Action Network
University of Florida College of Medicine
Indiana University School of Medicine
Ohio State University Wexner Medical Center
Cedars-Sinai Medical Center
National Institutes of Health (NIH)
National Childhood Cancer Registry – National Cancer Institute
University of Pittsburgh Medical Center
National Institute of Diabetes and Digestive and Kidney Diseases	R21DK122293, K01DK120737
Stanford University School of Medicine	R21DK122293, K01DK120737
Florida AandM University and Florida State University	U01DK108328
CPDPC	U01DK108306, U01DK108323, U01DK108314, U01DK108300, U01DK108288
Baylor College of Medicine	U01DK108327
Ohio Water Resources Center, Ohio State University	U01DK108320, U01DK108332
University of Southern Indiana	U01DK108326

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Good health and well being

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Hepatology
Endocrinology

Acceder al documento

10.1016/j.pan.2024.09.016

Otros archivos y enlaces

Citar esto

@article{1da67823aed7438b8a7f6c6ffd963798,

title = "Pancreatitis pain quality changes at year 1 follow-up, but GP130 remains a biomarker for pain",

abstract = "Background/objectives: Debilitating abdominal pain is a common symptom affecting patients with chronic pancreatitis (CP). CP pain is dynamic due to multiple underlying mechanisms. The objective of this study was to 1) evaluate changes in pain phenotype at one year follow-up and 2) validate putative pain biomarkers in a prospective cohort study. Methods: The Neuropathic and Nociceptive PROMIS-PQ questionnaires were used to classify pain for participants with in the PROCEED study. Putative serum biomarkers were measured via immunoassay. Results: At enrollment, 17.6 \% (120/681) subjects with CP reported no pain in the previous year. Of those, 29 \% experienced pain during the 1 yr follow-up whereas 18 \% of those with pain prior to enrollment reported no pain during the 1 yr follow-up period. Of the 393 subjects with PROMIS-PQ data at enrollment, 212 also had follow-up data at 1 yr. Approximately half (53.3 \%) of those individuals changed pain phenotype between baseline and follow-up. At 1 yr, serum TGFβ1 level was negatively correlated with nociceptive T-scores (p = 0.006). GP130 was significantly correlated with both nociceptive (p = 0.012) and neuropathic T-scores (p = 0.043) at 1 yr, which is consistent with the previously published findings. Conclusions: The positive association between TGFβ1 and pain is not maintained over time, suggesting it is a poor pain biomarker. However, serum GP130 is a consistent biomarker for mixed-type pain in CP. Preclinical studies show that targeting TGFβ1 or IL-6 (ligand for GP130) is sufficient to inhibit CP pain supporting further investigation of this as a potential therapeutic target.",

keywords = "Chronic pancreatitis, GP130, PROMIS-PQ, Pain",

author = "Saloman, \{Jami L.\} and Kristofer Jennings and Kimberly Stello and Shuang Li and \{Evans Phillips\}, Anna and Kristen Hall and Fogel, \{Evan L.\} and Vege, \{Santhi Swaroop\} and Andersen, \{Dana K.\} and Fisher, \{William E.\} and Forsmark, \{Christopher E.\} and Hart, \{Phil A.\} and Pandol, \{Stephen J.\} and Park, \{Walter G.\} and Topazian, \{Mark D.\} and \{Van Den Eeden\}, \{Stephen K.\} and Jose Serrano and Conwell, \{Darwin L.\} and Liang Li and Dhiraj Yadav",

note = "Publisher Copyright: {\textcopyright} 2024 IAP and EPC",

year = "2024",

month = nov,

doi = "10.1016/j.pan.2024.09.016",

language = "English",

volume = "24",

pages = "993--1002",

journal = "Pancreatology",

issn = "1424-3903",

publisher = "Elsevier BV",

number = "7",

}

TY - JOUR

T1 - Pancreatitis pain quality changes at year 1 follow-up, but GP130 remains a biomarker for pain

AU - Saloman, Jami L.

AU - Jennings, Kristofer

AU - Stello, Kimberly

AU - Li, Shuang

AU - Evans Phillips, Anna

AU - Hall, Kristen

AU - Fogel, Evan L.

AU - Vege, Santhi Swaroop

AU - Andersen, Dana K.

AU - Fisher, William E.

AU - Forsmark, Christopher E.

AU - Hart, Phil A.

AU - Pandol, Stephen J.

AU - Park, Walter G.

AU - Topazian, Mark D.

AU - Van Den Eeden, Stephen K.

AU - Serrano, Jose

AU - Conwell, Darwin L.

AU - Li, Liang

AU - Yadav, Dhiraj

PY - 2024/11

Y1 - 2024/11

N2 - Background/objectives: Debilitating abdominal pain is a common symptom affecting patients with chronic pancreatitis (CP). CP pain is dynamic due to multiple underlying mechanisms. The objective of this study was to 1) evaluate changes in pain phenotype at one year follow-up and 2) validate putative pain biomarkers in a prospective cohort study. Methods: The Neuropathic and Nociceptive PROMIS-PQ questionnaires were used to classify pain for participants with in the PROCEED study. Putative serum biomarkers were measured via immunoassay. Results: At enrollment, 17.6 % (120/681) subjects with CP reported no pain in the previous year. Of those, 29 % experienced pain during the 1 yr follow-up whereas 18 % of those with pain prior to enrollment reported no pain during the 1 yr follow-up period. Of the 393 subjects with PROMIS-PQ data at enrollment, 212 also had follow-up data at 1 yr. Approximately half (53.3 %) of those individuals changed pain phenotype between baseline and follow-up. At 1 yr, serum TGFβ1 level was negatively correlated with nociceptive T-scores (p = 0.006). GP130 was significantly correlated with both nociceptive (p = 0.012) and neuropathic T-scores (p = 0.043) at 1 yr, which is consistent with the previously published findings. Conclusions: The positive association between TGFβ1 and pain is not maintained over time, suggesting it is a poor pain biomarker. However, serum GP130 is a consistent biomarker for mixed-type pain in CP. Preclinical studies show that targeting TGFβ1 or IL-6 (ligand for GP130) is sufficient to inhibit CP pain supporting further investigation of this as a potential therapeutic target.

AB - Background/objectives: Debilitating abdominal pain is a common symptom affecting patients with chronic pancreatitis (CP). CP pain is dynamic due to multiple underlying mechanisms. The objective of this study was to 1) evaluate changes in pain phenotype at one year follow-up and 2) validate putative pain biomarkers in a prospective cohort study. Methods: The Neuropathic and Nociceptive PROMIS-PQ questionnaires were used to classify pain for participants with in the PROCEED study. Putative serum biomarkers were measured via immunoassay. Results: At enrollment, 17.6 % (120/681) subjects with CP reported no pain in the previous year. Of those, 29 % experienced pain during the 1 yr follow-up whereas 18 % of those with pain prior to enrollment reported no pain during the 1 yr follow-up period. Of the 393 subjects with PROMIS-PQ data at enrollment, 212 also had follow-up data at 1 yr. Approximately half (53.3 %) of those individuals changed pain phenotype between baseline and follow-up. At 1 yr, serum TGFβ1 level was negatively correlated with nociceptive T-scores (p = 0.006). GP130 was significantly correlated with both nociceptive (p = 0.012) and neuropathic T-scores (p = 0.043) at 1 yr, which is consistent with the previously published findings. Conclusions: The positive association between TGFβ1 and pain is not maintained over time, suggesting it is a poor pain biomarker. However, serum GP130 is a consistent biomarker for mixed-type pain in CP. Preclinical studies show that targeting TGFβ1 or IL-6 (ligand for GP130) is sufficient to inhibit CP pain supporting further investigation of this as a potential therapeutic target.

KW - Chronic pancreatitis

KW - GP130

KW - PROMIS-PQ

KW - Pain

UR - https://www.scopus.com/pages/publications/85204689139

UR - https://www.scopus.com/pages/publications/85204689139#tab=citedBy

U2 - 10.1016/j.pan.2024.09.016

DO - 10.1016/j.pan.2024.09.016

M3 - Article

C2 - 39322454

AN - SCOPUS:85204689139

SN - 1424-3903

VL - 24

SP - 993

EP - 1002

JO - Pancreatology

JF - Pancreatology

IS - 7

ER -

Pancreatitis pain quality changes at year 1 follow-up, but GP130 remains a biomarker for pain

Resumen

Nota bibliográfica

Financiación

ODS de las Naciones Unidas

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto